New cancer drug enters first human trials
NCT ID NCT07165067
Summary
This is the first human study of an experimental cancer drug called AP601. Researchers will test increasing doses in 36 patients with advanced solid tumors to find the highest safe amount. The main goal is to understand the drug's safety and how the body processes it, while also looking for early signs it might help control cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOURS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Calvary Mater Newcastle
NOT_YET_RECRUITINGWaratah, New South Wales, 2298, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Epworth HealthCare
RECRUITINGMelbourne, Victoria, 3121, Australia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Pindara Private Hospital
NOT_YET_RECRUITINGBrisbane, Queensland, 4217, Australia
Contact
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.